Ligand Pharmaceuticals Incorporated 13D and 13G filings for Seelos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-15 4:11 pm Unchanged | 2020-12-31 | 13G | Seelos Therapeutics, Inc. SEEL | LIGAND PHARMACEUTICALS INC LGND | 579 4.100% | 0 (Unchanged) | Filing |